Last reviewed · How we verify
YH002
At a glance
| Generic name | YH002 |
|---|---|
| Sponsor | Eucure (Beijing) Biopharma Co., Ltd |
| Modality | Small molecule |
| Phase | Phase 1 |
Approved indications
Common side effects
Key clinical trials
- A Study to Assess YH002 in Combination with YH001 in Subjects with Advanced Solid Tumors (PHASE1)
- A Study to Evaluate the Safety, Tolerability and How YH002 Enters, Moves Through and Exits the Body in Subjects With Advanced Solid Malignancies (PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- YH002 CI brief — competitive landscape report
- YH002 updates RSS · CI watch RSS
- Eucure (Beijing) Biopharma Co., Ltd portfolio CI